Supernus Pharmaceuticals is acquiring Sage Therapeutics, including its FDA-approved postpartum depression treatment, ZURZUVAE, for approximately $795 million.

Target Information

Sage Therapeutics, Inc. (Nasdaq: SAGE) is a biopharmaceutical company dedicated to developing and delivering innovative therapies for brain health disorders. Its flagship product, ZURZUVAE, is the first and only FDA-approved oral medication specifically indicated for the treatment of adults suffering from postpartum depression. This approval highlights Sage's commitment to addressing significant unmet medical needs in mental health treatments.

Under the terms of the agreement, Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) will acquire Sage, signaling confidence in Sage's product portfolio and future potential, especially regarding ZURZUVAE’s market accessibility and patient impact.

Industry Overview

The pharmaceutical industry in the United States has seen rapid growth, particularly in the mental health sector. With increasing awareness of mental health issues, the demand for effective treatments